Synthesis and cytotoxicity studies on new pyrazole-containing oxime ester derivatives

Arzu Karakurt1*, İrem Bozbey1, Harun Uslu1, Suat Sarı2, Zeynep Özdemir1, Emine Şalva3

1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İnönü University, 44280, Malatya, Turkey, 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, 06100, Ankara, Turkey, 3Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, İnönü University, 44280, Malatya, Turkey

*For correspondence: Email: arzukarakurt@hotmail.com; Tel: +904223410660-1720-7054

Abstract

Purpose: To synthesize a series of new 1-(2-naphthyl)-2-(1H-pyrazol-1-yl)ethanone oxime ester derivatives (5-12) with potential anticancer properties, and to determine their cytotoxic effects in mouse fibroblast and human neuroblastoma cell lines.

Methods: The title compounds were obtained through sodium salt reaction of 1-(naphthalene-2-yl)-2-(1H-pyrazol-1-yl)ethanone oxime (4) with various acyl chlorides. The cytotoxic effects were evaluated by MTS colorimetric assay, while physicochemical descriptors were calculated using QikProp software.

Results: Most of the compounds showed approximately 50 – 60 % inhibition against SH-SY5Y neuroblastoma cells at 100 μM. Of these, compound 7a was the most active combination with an IC50 value of 85.94 μM. The toxic effect of the compounds on mouse fibroblast cell line was insignificant (p < 0.05) even when the dose was increased. The calculated physicochemical properties of the compounds were within drug-like chemical space.

Conclusion: The synthesized oxime ester derivatives with pyrazole ring exhibit selective toxicity to neuroblastoma cells without affecting healthy mouse fibroblast cells. The compounds proved to be drug-like while their pharmacokinetic features were also encouraging, and were in line with in silico predictions.

Keywords: Cytotoxic activity, E/Z isomer, Neuroblastoma cell, Oxime ester, Pyrazole

INTRODUCTION

Neuroblastoma is an aggressive malignant tumor that originates in the early nerve cells of the sympathetic nervous system. Neuroblastoma often occurs in childhood and gives limited response to chemotherapy. The tumor is usually found to have metastasized by the time a diagnosis is made; as a result, survival rate is low in children with advanced neuroblastoma. Besides, the metastasized tumor commonly leads to unwanted side effects during chemotherapy. For these reasons, new and effective anticancer drugs need to be developed against neuroblastoma [1,2].
Heterocyclic compounds have been in use in medicinal chemistry as basic structures in the development of active molecules, many of which contain pyrazoles or pyrazole substitutes [3-6]. In addition, several effective molecules also contain oxime and oxime ester groups [7,8]. For example, some 2-(3,5-dimethyl-1H-pyrazol-1-yl)1-arylethanone derivatives are reported to be effective anticancer agents [8,9]. One of our own earlier studies, too, have shown cytotoxic activity in certain 3,5-dimethylpyrazole derivatives [10]. Building on the existing research results, this study analyses the 1-arylethanonepyrazole structure as a scaffold along with 12 new compounds containing oxime ester group. In order to evaluate their efficacy and selectivity against neuroblastoma cells, the preparations are tested in vitro for their cytotoxic effects against SH-SY5Y (human neuroblastoma) and L929 (mouse fibroblast) cell lines.

Physicochemical and pharmacokinetic profiles play a key role in the success of investigational compounds in the market, especially in studies on anticancer drug design [11]. To this end, our study also calculates the number of physicochemical and pharmacokinetic descriptors related to ADMET (Absorption, Distribution, Metabolism, Elimination, and Toxicity) properties.

**EXPERIMENTAL**

**Chemistry**

All reagents and solvents in this study were obtained from Aldrich, Merck, and Carlo Erba. All reactions were observed with analytical thin-layer chromatography using Merck Kieselgel 60 F254 plates. NMR spectra of the compounds were recorded with Bruker Avance 300 MHz Ultrashield™ NMR Spectrometers. All chemical shifts (δ) are reported in parts per million (ppm) using TMS as the internal reference. IR spectra were recorded with a Perkin Elmer Spectrum One FT-IR spectrophotometer using the attenuated total reflectance (ATR) FT-IR method. Elemental analyses were performed on a Leco CHNS-932 elemental analyzer.

2-Bromo-1-(naphthalene-2-yl)ethanone (2), 1-(naphthalene-2-yl)-2-(1H-pyrazol-1-yl)ethanone (3), 1-(naphthalene-2-yl)-2-(1H-pyrazol-1-yl) etanone oxime (4) were all synthesized in line with the methods existing in the literature [12-14].

**General synthesis of the compounds (5-12)**

0.011 mol metallic sodium (Na +) was dissolved in 10 ml absolute ethanol and 0.01 mol 4 was added; the mixture was heated under reflux for 1h and EtOH was evaporated. Then, 0.01 mol appropriate acyl chloride was added to the residue including sodium oximate. The mixture was dissolved in dry dichloromethane (DCM) and stirred for 12 h at room temperature. DCM was then evaporated and the acquired residue was treated with ethyl acetate. In the next step, the precipitate was filtered off, the solute was evaporated to dryness, and the residue was washed with diethyl ether. At this stage, the compounds were converted to HCl salts using ethereal solution of gaseous HCl (gHCl) (Figure 1).

**Figure 1**: Synthetic routes and molecular structures of compounds 5-12. Reagents and conditions are as follows: (i) CH3COOH, HBr, Br₂, 0-5 ° C to rt (ii) pyrazole, Dimethylformamide, 0-5 ° C to rt (iii) NH₂OH.HCl, EtOH, Ph = 14, reflux (iv) EtOH, Na₂CO₃, DCM, rt (v) gHCl

**Cytotoxic activity**

The initial aim of our study is to determine the cytotoxic effects of the compounds on human neuroblastoma cell line (SH-SY5Y) and mouse fibroblast cell line (L-929) by performing the MTS assay protocol (CellTiter 96 Single Solution, Promega, Madison, Wis.). To this end, the cells were stored in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10 % (v/v) heat-inactivated Fetal Bovine Serum (FBS) by Gibco. The cells were seeded 24h before the treatment with compounds of the attached cells into 96-well plate at a density of 5 x 10⁴ cells per well.

The compounds were then solubilized to 0.1 % as the final concentration form in dimethyl sulfoxide (DMSO). The medium at hand was replaced with fresh medium-containing compounds in 10, 25, 50 and 100 μM 10 % concentrations after 24 h of growth. Throughout the study vincristine was used as the positive control and the acquired medium as the negative control. Triplicate wells were prepared for the administration of each compound concentration.
The cells with the compounds were incubated at 5% CO\textsubscript{2} atmosphere at 37 °C for 48 h. At length, the MTS solution was added and the incubation of the cells was continued at 37 °C for 1 - 3 h. The absorbance of the cells was measured in an ELISA reader at 490 nm. The percentage of cell viability in test results was considered as the ratio of absorbance of the treated cells to the untreated control cells. In order to observe average cell viability, the results of the three experiments were averaged. To this extent, the concentration (μM) of the compounds causing 50% cell death relative to the control cultures yields the IC\textsubscript{50} value. The IC\textsubscript{50} values were calculated in accordance with the inhibition rates using GraphPad Prism 7.02 [15].

**Molecular modelling**

The ligands were sketched using 2D-Sketcher of Maestro (2018-1, Schrödinger, LLC, New York, NY, 2018), modelled and optimized using MacroModel (2018-1, Schrödinger, LLC, New York, NY, 2018). OPLS_2005 force field [16] QikProp was run in normal mode to calculate the descriptors throughout.

**RESULTS**

**Synthesis and spectral data**

1-Naphthalene-2-yl-2-bromoethanone (2) was prepared by brominating 2-acetynaphthalene (1). Compound 2 was converted to its ketone derivative (3) by N-alkylation of pyrazole. Then, compound 3 was converted to its oxime derivate (4) by refluxing with hydroxylamine hydrochloride (NH\textsubscript{2}OH.HCl) under alkaline conditions. The final compounds (5-12) were synthesized by sodium salt reaction of 1-(naphthalene-2-yl)-2-(1H-pyrazol-1-yl)ethanone oxime (4) with various acyl chlorides (Figure 1). The structures of 5-12 were determined by IR, 	extsuperscript{1}H-NMR, 	extsuperscript{13}C-NMR, and further elemental analyses (Tables 1 - 3).

**Table 1:** Chemical and physical data of compounds 5-12

| Compound | Config. | R            | Yield (%) | Mp (°C) | Molecular formula | Analyte (%) calculated | Analyte (%) found |
|----------|---------|--------------|-----------|---------|-------------------|------------------------|-------------------|
| 5        | Z       | phenyl       | 35.35     | 153-4   | C\textsubscript{22}H\textsubscript{17}N\textsubscript{3}O\textsubscript{2}.1/7CH\textsubscript{2}Cl\textsubscript{2} | 72.36                | 4.74              | 11.43             |
|          |         |              |           |         |                   | 72.92                | 4.57              | 11.80             |
| 6        | E/Z     | 2-methylphenyl | 47.61     | 150     | C\textsubscript{22}H\textsubscript{19}F\textsubscript{3}N\textsubscript{2}O\textsubscript{2} | 74.78                | 5.18              | 11.37             |
|          |         |              |           |         |                   | 74.52                | 5.10              | 11.21             |
| 7a       | Z       | 2-fluorophenyl | 21.39     | 139-41  | C\textsubscript{22}H\textsubscript{16}F\textsubscript{2}N\textsubscript{3}O\textsubscript{2}.1/8CH\textsubscript{2}Cl\textsubscript{2} | 69.20                | 4.27              | 10.94             |
|          |         |              |           |         |                   | 69.14                | 4.18              | 11.22             |
| 7b       | E/Z     | 2-fluorophenyl | 10.10     | 132     | C\textsubscript{22}H\textsubscript{17}ClF\textsubscript{2}N\textsubscript{2}O\textsubscript{2} | 64.47                | 4.18              | 10.25             |
|          |         |              |           |         |                   | 64.59                | 4.28              | 10.27             |
| 8a       | Z       | 3-fluorophenyl | 26.24     | 128-130 | C\textsubscript{22}H\textsubscript{16}F\textsubscript{2}N\textsubscript{3}O\textsubscript{2}.1/12CH\textsubscript{2}Cl\textsubscript{2} | 69.72                | 4.28              | 10.04             |
|          |         |              |           |         |                   | 69.80                | 4.08              | 11.32             |
| 8b       | E/Z     | 3-fluorophenyl | 7.67      | 120-1   | C\textsubscript{22}H\textsubscript{17}ClF\textsubscript{2}N\textsubscript{2}O\textsubscript{2} | 64.47                | 4.18              | 10.25             |
|          |         |              |           |         |                   | 64.71                | 4.24              | 10.48             |
| 9a       | Z       | 3-chlorophenyl | 23.87     | 130-2   | C\textsubscript{22}H\textsubscript{16}ClN\textsubscript{2}O\textsubscript{2} | 67.78                | 4.14              | 10.78             |
|          |         |              |           |         |                   | 67.53                | 4.14              | 10.59             |
| 9b       | E/Z     | 3-chlorophenyl | 6.48      | 108     | C\textsubscript{22}H\textsubscript{17}Cl\textsubscript{2}N\textsubscript{2}O\textsubscript{2} | 61.99                | 4.02              | 9.86              |
|          |         |              |           |         |                   | 62.84                | 4.13              | 9.63              |
| 10       | Z       | 4-chlorophenyl | 74.08     | 172-4   | C\textsubscript{22}H\textsubscript{16}ClN\textsubscript{2}O\textsubscript{2}.2CH\textsubscript{2}Cl\textsubscript{2} | 51.50                | 3.60              | 7.51              |
|          |         |              |           |         |                   | 51.32                | 3.36              | 7.64              |
| 11       | Z       | 2,4-dichlorophenyl | 20.51   | 126-7   | C\textsubscript{22}H\textsubscript{15}Cl\textsubscript{2}N\textsubscript{2}O\textsubscript{2}.1/6CH\textsubscript{2}Cl\textsubscript{2} | 60.73                | 3.53              | 9.58              |
|          |         |              |           |         |                   | 61.00                | 3.59              | 9.67              |
| 12       | E       | 2-chlorophenyl | 40.97     | 144-5   | C\textsubscript{22}H\textsubscript{17}Cl\textsubscript{2}N\textsubscript{2}O\textsubscript{2}.1CH\textsubscript{2}Cl\textsubscript{2} | 54.04                | 3.75              | 8.22              |
|          |         |              |           |         |                   | 54.32                | 3.71              | 8.45              |
Table 2: $^1$H-NMR data of compound 5-12 (DMSO-$d_6$, 300 MHz)

| Comp. | $-\text{CH}_3$ | $-\text{CH}_2\text{N}$ (2H; s) | $\text{H}^+$ (1H; t) | $\text{H}^+$ (1H; d) | Naphthalene aromatic H | $\text{H}^+$ (1H; s) |
|-------|----------------|---------------------------------|---------------------|---------------------|----------------------|-----------------|
| 5     |                | 5.94                            | 6.18                | 7.39                | 7.57-8.18            | 8.43            |
| 6     | 2.32 (3H; s)  | 5.62 (78.13%)                   | 5.87 (21.87%)       | 6.15                | 7.37                | 7.14-8.01       |
| 7a    |                | 5.89                            | 6.17                | 7.37                | 7.41-8.13            | 8.39            |
| 7b    |                | 5.63 (47.40%)                   | 5.89 (52.60%)       | 6.16                | 7.25                | 7.28-8.09       |
| 8a    |                | 5.96                            | 6.18                | 7.39                | 7.57-8.03            | 8.44            |
| 8b    |                | 5.65 (48.78%)                   | 5.96 (51.22%)       | 6.19                | 7.40                | 7.57-8.15       |
| 9a    |                | 5.66 (67.11%)                   | 5.96 (32.89%)       | 6.19                | 7.39                | 7.47-8.17       |
| 9b    |                | 5.66                            | 5.95                | 6.17                | 7.38                | 7.58-8.18       |
| 10    |                | 5.87                            | 6.17                | 7.37                | 7.38-8.07            | 8.43            |
| 11    |                | 5.62                            | 6.11                | 7.37                | 7.33-7.91            | 8.06            |
| 12    |                |                                 |                     |                     |                      |                 |

For the purification of compounds 5-12, the residue obtained by evaporation of DCM was first extracted from ethyl acetate, in which sodium chloride precipitated and the oxime ester derivatives dissolved. The ethyl acetate was then evaporated and the resulting residue was treated with diethyl ether, on which most of the derivatives solidified. The majority of the precipitated materials following diethyl ether washing were in Z configuration. The ethereal solution was treated with gHCl to convert the dissolved derivatives to their salt forms. The application gave compound 12 as pure E and compounds 7b, 8b, 9b as E/Z mixtures. This suggests that gHCl could trigger interconversion of diastereomers depending on several factors such as solvation, temperature etc.

Table 3: IR and $^{13}$C-NMR Spectral data of the compound 5-12

| Compd | IR (ATR) C=O (cm$^{-1}$) | $^{13}$C-NMR (DMSO-$d_6$, 300 MHz) |
|-------|--------------------------|-------------------------------------|
| 5     | 1742                     |                                     |
| 6     | 1740                     |                                     |
| 7a    | 1733                     |                                     |
| 7b    | 1733                     |                                     |
| 8a    | 1742                     |                                     |
| 8b    | 1751                     |                                     |
| 9a    | 1742                     |                                     |
| 9b    | 1756                     |                                     |
| 10    | 1739                     |                                     |
| 11    | 1761                     |                                     |
| 12    | 1754                     |                                     |
The E/Z configuration of each compound was determined according to the chemical shift of singlet of methylene protons (−CH$_2$−N) between the oxime ester group and the pyrazole ring. The −CH$_2$−N protons of compound 6, for instance, were observed as two singlets with a down field peak at 5.87 ppm and an up field peak at 5.62 ppm. At this point, the differences in the chemical shift values were dependent on the angle between the C-H bond and the C=N-OH plane. The proton, sharing the same side with the aromatic group, shifted to higher ppm because of the anisotropic effect of the aromatic group. Here, the intensities of the two singlet peaks were 21.87% and 78.13%, respectively. The intensity values were calculated by the ratio of peak integrals. These configurations of the compounds (E or Z) as well as their chemical shifts were also calculated (Table 4).

Since the synthesized compounds were β-naphthyl derivatives, the protons (H$_1$ and H$_2$-8) of the naphthalene ring were observed between 7.0 - 8.2 ppm in accordance with the results of existing research in the literature. The H$_4$ proton of the pyrazole was observed in triplets at about 6.11-6.19 ppm, while H$_5$ protons were observed in the aromatic field. Yet, the pyrazole H$_5$ was seen between 8.06-8.45 ppm. This shift was due to the configuration of the structure as it was affected by the electronegativity of the oxygen.

**In vitro cytotoxic activity**

Cytotoxic and anticancer effects of the synthesized compounds were tested at four concentrations (10, 25, 50 and 100 μM) and the IC$_{50}$ values were determined accordingly. The results of cytotoxic activity against SH-SY5Y (human neuroblastoma) and L929 (mouse fibroblast cell line) cells are shown in Table 5.

According to this, the compounds were effective against the SH-SY5Y cell line. In addition, they did not show significant toxicity against healthy fibroblast cells despite increasing doses, which indicates selectivity towards cancerous cells (Table 5). 2-fluorobenzoyl derivative (7a) was the most active compound throughout with a potency comparable to the positive control, vincristine. This compound inhibited approximately 50% of cancerous cells at 100 μM (IC$_{50}$ = 85.94 μM) (Figure 2). 7a also presented the best selectivity index against the SH-SY5Y cell line with a SI value of 9.33 as shown in Table 5.

| Compound | Chemical shift | Intensity | Chemical shift | Intensity |
|----------|----------------|-----------|----------------|-----------|
|          | (ppm)          | (%)       | (ppm)          | (%)       |
| 5        |                |           | 5.94           | 100       |
| 6        | 5.62           | 78.13     | 5.87           | 21.87     |
| 7a       |                |           | 5.89           | 100       |
| 7b       | 5.63           | 47.40     | 5.89           | 52.60     |
| 8a       |                |           | 5.96           | 100       |
| 8b       | 5.69           | 48.47     | 5.96           | 51.22     |
| 9a       |                |           | 5.96           | 100       |
| 9b       | 5.66           | 67.11     | 5.96           | 32.89     |
| 10       |                |           | 5.95           | 100       |
| 11       |                |           | 5.87           | 100       |
| 12       | 5.62           | 100       |                |           |
activities of derivatives featuring similar linking a naphthalene and pyrazole ring. There 

Table 5: Cell viability (%) of SH-SY5Y and L929 cell line treated with 5-12 and vincristine.

| Compound | Cell line | 10 μM | 25 μM | 50 μM | 100 μM | IC_{50} | SI |
|----------|-----------|-------|-------|-------|--------|--------|----|
| 5        | SH-SY5Y   | 84.09 | 86.88 | 84.78 | 63.24  | 184.20 |   |
|          | L929      | 105.79| 101.05| 103.62| 103.84 | -      |    |
| 6        | SH-SY5Y   | 82.85 | 93.65 | 89.06 | 68.87  | 250.20 |   |
|          | L929      | 93.99 | 97.21 | 103.85| 101.16 | -      |    |
| 7a       | SH-SY5Y   | 81.90 | 74.58 | 63.76 | 50.63  | 85.94  | 9.33|
|          | L929      | 90.48 | 88.76 | 92.13 | 93.494 | 801.40 |    |
| 7b       | SH-SY5Y   | 105.94| 95.24 | 81.21 | 58.25  | 188.50 | 11.7|
|          | L929      | 98.13 | 100.06| 98.09 | 95.332 | 2202   |    |
| 8a       | SH-SY5Y   | 75.67 | 76.15 | 76.34 | 77.11  | 189.50 | 11.6|
|          | L929      | 95.94 | 96.45 | 96.82 | 97.18  | 2196   |    |
| 8b       | SH-SY5Y   | 95.88 | 97.45 | 79.42 | 54.83  | 165.40 | 19.1|
|          | L929      | 96.05 | 96.48 | 96.79 | 97.09  | 2161   |    |
| 9a       | SH-SY5Y   | 95.20 | 96.62 | 88.87 | 81.49  | 455.10 | 1.76|
|          | L929      | 85.52 | 97.95 | 90.28 | 92.39  | 800.10 |    |
| 9b       | SH-SY5Y   | 79.79 | 96.35 | 94.62 | 57.03  | 205.20 |   |
|          | L929      | 107.89| 100.35| 135.20| 115.88 | -      |    |
| 10       | SH-SY5Y   | 84.19 | 96.17 | 92.14 | 108.30 | -      |    |
|          | L929      | 81.59 | 82.41 | 63.39 | 63.77  | 119.80 | 1.31|
| 11       | SH-SY5Y   | 91.90 | 78.62 | 79.35 | 81.19  | 260.90 |   |
|          | L929      | 62.79 | 83.39 | 73.96 | 60.58  | 122.00 | 2.80|
| 12       | SH-SY5Y   | 79.71 | 92.72 | 84.71 | 81.90  | 341.90 |   |
|          | L929      | 50.59 | 48.27 | 43.53 | 36.86  | 25.52  | 3.37|
| Vincristine | SH-SY5Y   | 70.67 | 65.80 | 63.02 | 61.70  | 85.94  |   |

Table 6: A selection of descriptor values calculated for 5, 7a, 8a, 9a, and 10-12.

| Property/ descriptor | Recommended values range | 5   | 7a  | 8a  | 9a  | 10  | 11  | 12  |
|----------------------|--------------------------|-----|-----|-----|-----|-----|-----|-----|
| #stars               | -5                       | 0   | 1   | 1   | 2   | 2   | 2   | 1   |
| #rtvFG               | 0.2                      | 1   | 1   | 1   | 1   | 1   | 1   | 1   |
|QPlogPo/w             | -2.0 to 6.5              | 4.53| 4.77| 4.80| 5.05| 5.04| 5.40| 4.99|
|QPlogS                | -6.5 to 0.5              | -5.09| -5.38| -5.50| -5.83| -6.86| -6.15| -5.69|
|QPlogHERG             | concern below -5         | -7.23| -7.14| -7.13| -7.13| -7.13| -7.13| -7.00|
|QPPCaco               | >500 great               | 1929| 2111| 1969| 1983| 1927| 2152| 1849|
|QPlogBB               | -3.0 to 1.2              | -0.56| -0.43| -0.44| -0.39| -0.40| -0.23| -0.43|
|QPMDCK                | >500 great               | 1007| 1746| 1857| 2516| 2483| 4959| 2043|
|#metab               | 1 to 8                   | 1   | 1   | 1   | 1   | 1   | 1   | 1   |
|%HOA                  | >80% is high             | 100| 100| 100| 100| 100| 100| 100|
|RuleOFive             | the lower the better      | 0   | 0   | 0   | 1   | 1   | 1   | 0   |

#stars: Number of descriptors that fall outside the recommended values vary (See additional information for details). #rtvFG: Number of functional groups that may cause non-specific reactions. QPlogPo/w: Predicted LogP. QPlogS: Predicted water solubility (S in mol/dm^3). QPlogHERG: Predicted HERG K^+ IC_{50}. QPPCaco: Predicted permeability in Caco-2 cell model (nm/sec). QPlogBB: Predicted partition coefficient for brain/blood. QPMDCK: Predicted permeability in MDCK cell model (nm/sec). #metab: Number expected metabolic reactions. %HOA: Predicted human oral absorption (0 to 100%). RuleOFive: Number of Lipinski’s rule of five violations [19]

DISCUSSION

The title compounds used in this study carry oxime ester derivatives of the ethylene group linking a naphthalene and pyrazole ring. There are several studies in the literature on anticonvulsant, antibacterial, and antifungal activities of derivatives featuring similar skeletons. In addition, the presence of anticarcinogenic activity in numerous heterocyclic compounds containing oxime ester structures have also been investigated in recent years. A 2001 study on a series of synthetic 2,3,4-trimethoxyacetophenoxime esters containing benzothiazole ring reports antitumor activities through inhibition of extracellular signal-regulated kinase (ERK) phosphorylation in mouse embryonic fibroblast cells (NIH 3T3) (20).

Using human embryonic stem cell line (HSF cell line) to investigate the cytotoxic effects of compounds on healthy cells, another study reports that some of the compounds showed strong cytotoxic effect in comparison to the
reference drug, 5-FU after synthesizing and evaluating a series of 1,4-naphthoquinone oxime-derived compounds for their antitumor activities and in colorectal carcinoma cell lines (21). A similar study synthesizing 1-aryl-2-(3,5-dimethyl-1H-pyrazol-1-yl)ethanone derivatives with high yields to monitor their cytotoxic activities against lung (A549), colon (HCT116 and HT29), prostate (DU145) and ovarian (SKOV3) cancer cell lines argues that the naphthalene-containing derivatives were reportedly the most effective compounds against all cell lines. According to the researchers, 1-Naphthyl and 2-naphthyl derivatives were the most effective compounds in the series while they were also as potent as the standard drug carboplatin against lung (A549) cell lines (22). In the present study, too, we synthesized a series of compounds containing oxime ester and a heterocyclic ring similar to the above-mentioned combinations in order to examine their cytotoxic activities on neuroblastoma cells. In line with the corresponding studies in the literature, our findings show toxicity to neuroblastoma cells at low concentrations. Throughout the tests, we used healthy fibroblast cells to investigate their possible toxic effect and found that they showed selective toxicity to neuroblastoma cells without affecting healthy cells, which proved the therapeutic reliability of our compounds.

Our study differs from the existing studies in its attempt to determine theoretical diastereomer ratio of the oxime components, which has remained a rare research concern in the literature to this day. The compounds converted to their HCl salts were obtained as either E isomer or E/Z mixtures while those in the parent form were only in Z configuration. These results suggest that gHCl has the potential to bring about interconversion in diastereomers possibly due to several factors such as solvation, temperature etc. E/Z configuration of each compound was determined according to the chemical shift of the singlet of methylene protons (-CH$_2$-N) between the oxime ester group and the pyrazole ring.

Additionally, the compounds were drug-like and predicated to have favorable pharmacokinetics according to the in silico calculations. Our results demonstrate that the compounds showed favorable pharmacokinetic properties, such as blood-brain partition, aqueous solubility, gut-blood barrier permeability, and oral absorption. Most of the physicochemical and pharmacokinetic properties/descriptors of these compounds were within the limits indicated by the experimental values of known drugs and the compounds were drug-like. On the other hand, a number of calculations yielded negative results. For example, the solvent accessible surface area values of the compounds fell outside the recommended value range; the oxime ester linker was identified as a nonspecific reactive functional group (#rtvFG); and the compounds were predicted to be potential hERG inhibitors (QPlogHERG). It should also be noted that 9a, 10, and 11 violated Lipinski’s Rule of 5 with slightly higher QPlogPo/w values.

Based on the results of our study, it can be suggested that the azole ring and oxime ether structure should be revised in future studies.

CONCLUSION

The findings of the study show that the cytotoxic effects of the compounds on human neuroblastoma (SH-SY5Y) and fibroblast (L929), indicate that a majority of the compounds exhibit selective cytotoxicity to neuroblastoma cells without significantly affecting fibroblast cell line. The compounds initially had been predicted to be drug-like and to have favorable ADMET properties and this has indeed been confirmed this projection. Thus, more effective compounds can be designed and synthesized through various modifications.

DECLARATIONS

Acknowledgement

This work was supported by Inonu University Scientific Research Projects Coordination Unit (Project no. 2011/65).

Conflict of interest

No conflict of interest is associated with this work.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/rea
REFERENCES

1. Fizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology (Neuroblastoma), 4th Edition. Philadelphia: Lippincott-Raven; 2001. pp. 895-937.

2. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24: 65-86.

3. Gaba M, Mohan C. Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions. Med Chem Res 2016; 25: 173-210.

4. Shalmani N, Rahmat A, Sandhya B. Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development. Mini Rev Med Chem 2018; 18: 142-163.

5. Shen S-L, Zhu J, M Li, Zhao BZ, Miao JY. Synthesis of ferrocenyl pyrazole-containing chiral aminoanethol derivatives and their inhibition against A549 and H322 lung cancer cells. Eur J Med Chem 2012; 54: 287-294.

6. Lingaiah N, Gaikwad HK, Sankonda K, Matei J, Bantu R, Raghu PS, Manda KM, Kalvendi SV. Synthesis and cytotoxicity evaluation of 1-[3-(9H-carbazol-4-yl oxy)-2-hydroxypropyl]-3-aryl-1H-pyrazole-5-carboxylic acid derivatives. Eur J Med Chem 2010; 45: 4720-4725.

7. Abele E, Abele R, Lukevics E. Oximes of five-membered heterocyclic compounds with three and four heteroatoms 1. Synthesis and structure. Chem Heterocycl Comp 2008; 44: 637-649.

8. Zheng LW, Li Y, Ge D, Zhao BX, Liu YR, Lv HS, Ding J, Miao JY. Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells. Bioorg Med Chem Lett 2010; 20: 4768-4770.

9. Kumar V, Kaur K., Karelia DN, Beniwal V, Gupta GK, Sharma AK, Gupta AK. Synthesis and biological evaluation of some 2-(3,5-dimethyl-1H-pyrazol-1-yl)-1-arylethanones: Antibacterial, DNA photocleavage, and anticancer activities. Eur J Med Chem 2014; 81: 267-276.

10. Alagöz MA. Synthesis of New Compounds of 1-Aryl-2-(3,5-dimethylpyrazol-1-yl)Ethanon Derivatives and Investigation of Cytotoxic Effects. Doctoral thesis, 2017: Inonu University, Malatya, Turkey.

11. Lin JH, Lu SY. Role of Pharmacokinetics and Metabolism in Drug Discovery and Development. Pharmacological Reviews 1997; 49(4): 403-449.

12. Immediata T, Day AR. β-Naphthyl Derivatives of Ethanolamine and N-Substituted Ethanolamines. J Org Chem 1940; 5: 512-527.

13. Çalış Ü, Dalkara S, Ertan M, Sunal R. The Significance of the Imidazole Ring in Anticonvulsant Activity of (Arylalkyl)imidazoles. Arch Pharm (Weinheim) 1988; 321: 841-846.

14. Özdemir Z, Karakurt A, Çalış Ü, Günel S, Işık Ş, Şahin ZŞ, Dalkara S. Synthesis, Anticonvulsant and Antimicrobial Activities of Some New [1-(2-Naphthyl)-2- (pyrazol-1-yl)ethanone]oxime Ethers. Med Chem 2015; 11: 41-49.

15. Karakuş S, Tok F, Türk S, Salva E, Tatar G, Taskin-Tok T, Kaymakçıoğlu-Koçyiğit B. Synthesis, anticancer activity and ADME studies of N-(5-methyl-1,3,4-thiadiazol-2-yl)-4-[3(substituted)ureido/thiourea]benzenesulfonylamine derivatives. Phosphorus Sulfur 2018; 193(6): 528-534.

16. Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R, Feltis AK, Halgren TA, Mainz DT, Maple JR. Integrated modeling program, applied chemical theory (IMPACT). J Comput Chem 2005; 26: 1752-1780.

17. Duffy EM, Jorgensen WL. Prediction of Properties from Simulations: Free Energies of Solvation in Hexadecane, Octanol, and Water. J Am Chem Soc 2010; 122: 2878-2888.

18. Jorgensen WL, Duffy EM. Prediction of Drug Solubility from Monte Carlo Simulations. Bioorg Med Chem Lett 2000; 10: 1155-1158.

19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2001; 46: 3-26.

20. Song BA, Liu XH, Yang S, Hu DY, Jin LH, Zhang H. Synthesis and Anticancer Activity of 2,3,4-Trimethoxycyclopenoxime Ester Containing Benzothiazole Moiety. Chinese J Chem 2005; 23: 1236-1240.

21. Huang G, Zhao HR, Li SS. Synthesis and Cytotoxicity of 6-Substituted 1,4-Naphthoquinone Oxime Derivatives (II)1. Russ J Gen Chem 2017; 87, (12): 2979-2985.

22. Kumar V, Kaur K, Karelia DN, Beniwal V, Gupta G, Sharma AK, Gupta A. Synthesis and biological evaluation of some 2-(3,5-dimethyl-1H-pyrazol-1-yl)-1-arylethanones: antibacterial, DNA photocleavage, and anticancer activities. Eur J Med Chem 2014; 81: 267-76.